ReviewOpen forum infectious diseases2022
Overcoming
Review in Open forum infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Global mapping of antibiotic resistance rates among clinical isolates of Stenotrophomonas maltophilia: a systematic review and meta-analysis.Annals of clinical microbiology and antimicrobials · 2024Pooled it
- Association between antimicrobial regimens and 28-day mortality in patients withMicrobiology spectrum · 2026Article
- Antimicrobial resistance mechanisms, treatment challenges, and emerging strategies inFrontiers in cellular and infection microbiology · 2026Review
- Integrated genomic analysis ofFrontiers in microbiology · 2026Article
- Review
- Comparative evaluation of definitive therapy for deep-seatedJAC-antimicrobial resistance · 2025Article
- Propensity-Matched Comparison of Timely vs Delayed Antibiotic Therapy inOpen forum infectious diseases · 2025Article
- Clinical Characteristics of Patients with Intra-Abdominal Infection Caused byJournal of clinical medicine · 2025Article
- Optimizing Antibiotic Therapy forAntibiotics (Basel, Switzerland) · 2024Article
- Article
- Characterization and genomic analysis of a lyticFrontiers in microbiology · 2024Article
- A pan-genomic analysis based multi-epitope vaccine development by targetingIn silico pharmacology · 2024Article
- Antibiotic utilization trends in Veterans Affairs patients withAntimicrobial stewardship & healthcare epidemiology : ASHE · 2024Article
- Antibiotic Resistance and Virulence Factors in Clinical Isolates ofInternational journal of microbiology · 2024Article
- Prediction and characterization of prophages of Stenotrophomonas maltophilia reveals a remarkable phylogenetic diversity of prophages.Scientific reports · 2023Article
- Editorial for the Special Issue: "The Issue of Multidrug-Resistant Pathogens in Nosocomial Infections".Antibiotics (Basel, Switzerland) · 2023Article
- Dissemination and characterization ofPolish journal of microbiology · 2023Article
- Cefiderocol Treatment for Severe Infections due to Difficult-to-Treat-Resistant Non-Fermentative Gram-Negative Bacilli in ICU Patients: A Case Series and Narrative Literature Review.Antibiotics (Basel, Switzerland) · 2023Review
- Review
- Intra-Abdominal Abscess and Bacteremia Due toInfection and drug resistance · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.